Stock Selection: GPT-6's picks for 2026-10-29
GPT-6 picked LLY, RSP, CROX, NCLH, GKOS for a 1-day horizon. Portfolio return vs SPY: +2.81%. Picks that beat SPY: 80%.
| Experiment | Stock Selection |
|---|---|
| Model | GPT-6 |
| Prompt version | stock-selection-v8 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-29 |
| Measured to | 2026-10-30 |
| Benchmark | SPY |
| Status | Settled |
| Portfolio return vs SPY | +2.81% |
| Picks that beat SPY | 80% |
| Benchmark return | -1.50% |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | LLY | +3.17% | 66% | +4.67% | Yes |
| 2 | RSP | -0.33% | 63% | +1.17% | Yes |
| 3 | CROX | +3.21% | 60% | +4.71% | Yes |
| 4 | NCLH | -2.29% | 59% | -0.79% | No |
| 5 | GKOS | +2.82% | 55% | +4.32% | Yes |
The model's market view
I favor positive earnings revisions and broader market participation over SPY's concentrated mega-cap exposure. Alphabet's earnings-related selloff is weighing on the indexes while many other stocks remain stronger. The main risk is a rapid mega-cap recovery that lifts SPY. These forecasts concern further performance over the remaining window; earlier gains are already realized, and exact window-start prices were not verified. Allocate 20% to each selection.
Why each pick
LLY
Lilly reported 39% revenue growth and increased its annual revenue guidance midpoint by $5.5 billion, supported by Mounjaro and Zepbound demand. I expect continued earnings reassessment to support outperformance against SPY, although the substantial initial advance is already priced in. Risks include profit-taking, drug-pricing pressure and earnings-quality complications: quarterly revenue included approximately $900 million of benefits, while acquisition charges reduced the final EPS guidance range despite improved underlying expectations. The reference is a regular-session intraday snapshot labeled real-time by the provider, approximately seven minutes old at the research cutoff.
RSP
RSP's equal-weight approach reduces the influence of the largest companies compared with SPY. I expect the current split between weak mega-cap technology and firmer broader participation to persist through the remaining window, supporting relative outperformance without relying on another large individual earnings jump. This is a market-structure inference, not a new company catalyst. Risks are a strong mega-cap rebound or selling spreading to the broader market. The reference is a regular-session intraday snapshot labeled real-time by the provider, approximately eight minutes old at the research cutoff.
CROX
Crocs raised annual adjusted EPS guidance to $14.45–14.65 from $13.70–14.00, while HEYDUDE returned to growth with a 6% quarterly revenue increase. These substantive improvements could sustain buying and earnings-estimate revisions after the initial reaction, producing further outperformance against SPY. However, the observed roughly 24% daily advance already reflects substantial optimism; profit-taking, consumer weakness and reliance on tariff refunds or cost benefits could limit follow-through. The reference is a regular-session intraday snapshot labeled real-time by the provider, approximately nine minutes old at the research cutoff.
NCLH
Norwegian delivered results above its guidance, including adjusted EPS of $1.12, and raised annual adjusted EPS guidance to approximately $1.70 and adjusted EBITDA guidance to approximately $2.55 billion. I expect the improved operating outlook to attract additional demand relative to SPY over the remaining window. Today's double-digit advance is already realized and increases reversal risk. Other risks include leverage, fuel-price volatility and changes in travel demand. The reference is a regular-session intraday snapshot labeled real-time by the provider, approximately 14 minutes old at the research cutoff.
GKOS
Glaukos reported record quarterly sales of $211 million, up 58%, and positive GAAP net income, alongside non-GAAP EPS of $0.47. The combination supports a substantive reassessment of commercial growth and profitability, which could extend its relative strength against SPY. It ranks fifth because the observed nearly 30% daily advance has already captured considerable good news; further outperformance is an inference, not an implication of that past gain. Valuation sensitivity, commercialization execution and sharp profit-taking are the main risks. The reference is a regular-session intraday snapshot labeled real-time by the provider, approximately five minutes old at the research cutoff.
Other models on the same run
| Model | Picks | Portfolio return vs SPY | Picks that beat SPY |
|---|---|---|---|
| Muse Spark 1.1 | LLY, PWR, MA, MRK, VRT | +0.22% | 60% |
| Claude Sonnet 5.5 | XLE, RSP, IWM, MSFT, NVDA | +0.64% | 60% |
| Gemini 3.6 Flash High | NVDA, AMD, MSFT, QQQ, AMZN | -2.61% | 20% |
| Perplexity | XLP, WMT, GLD, NVDA, QQQ | +0.45% | 40% |
| DeepSeek | LLY, MRK, LHX, XEL, AMZN | +1.95% | 80% |
Written up on ForecastNest Insights: Stock Selection: GPT-6's picks for 2026-10-29.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.